Keywords: arimidex, outdoes, tamoxifen, study, astrazeneca, reported, clinical
Arimidex outdoes tamoxifen in study
Article | 13 December 2001
AstraZeneca has reported clinical trial data which indicate, for thefirst time, that its aromatase inhibitor Arimidex (anastrozole) is more effective ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
